meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
Comparator:
vs Standard of Care (SoC);
vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;